Reta

Reta is a GLP-1 receptor agonist that mimics the effects of native GLP-1, a hormone secreted by the intestinal L-cells in response to nutrient ingestion. By binding to and activating the GLP-1 receptor, Reta stimulates insulin secretion from pancreatic beta-cells in a glucose-dependent manner, while simultaneously inhibiting glucagon secretion from pancreatic alpha-cells. This dual action helps to regulate blood glucose levels and improve glucose homeostasis. In addition to its effects on glucose metabolism, Reta also promotes satiety and reduces food intake by acting on GLP-1 receptors in the hypothalamus, a key region of the brain involved in appetite regulation. By increasing feelings of fullness and reducing hunger, Reta can lead to measurable changes in body weight.

Furthermore, Reta has been shown to exert anti-inflammatory effects by modulating immune cell function and reducing the production of pro-inflammatory cytokines. This anti-inflammatory action may contribute to its beneficial effects on metabolic health, as chronic low-grade inflammation is a hallmark of obesity and related disorders.

• Measurable change in body weight: Reta has demonstrated the ability to promote measurable changes in body weight in preclinical studies, making it a promising candidate in studies of obesity.

• Improved glucose homeostasis: By enhancing insulin secretion and inhibiting glucagon secretion, Reta helps to regulate blood glucose levels and improve glucose tolerance, which is particularly beneficial for study subjects with type 2 diabetes.

• Reduced inflammation: The anti-inflammatory properties of Reta may help to mitigate the chronic low-grade inflammation associated with obesity, thereby reducing the risk of developing obesity-related comorbidities.

• Enhanced stability and half-life: Reta has been engineered to exhibit improved stability and a prolonged half-life compared to native GLP-1, allowing for less frequent dosing in study protocols.

• Targeted approach to metabolic health: By selectively targeting the GLP-1 receptor, Reta offers a targeted approach to managing obesity and related metabolic disorders, minimizing the risk of off-target effects.

This section describes laboratory handling. It is not clinical guidance, and no safety claim for human or veterinary administration is made or implied.

• Supplied lyophilized. Reconstituted peptide solutions have materially shorter working stability than the dry powder — prepare working aliquots and avoid repeated freeze-thaw cycles.

• Handle as a research chemical of undetermined hazard. Use gloves, eye protection and a laboratory coat.

• Storage temperature and, where applicable, reconstitution conditions are stated on the item specification sheet and the lot Certificate of Analysis, which take precedence over general guidance.

• Dispose of unused material and consumables in accordance with the institutional chemical waste policy.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement.

Reta is a promising novel peptide that targets the GLP-1 receptor in studies of obesity and related metabolic disorders. Reta is studied as a GLP-1 receptor agonist; published work has measured endpoints relating to body weight, glucose homeostasis and inflammatory markers. Its enhanced stability and prolonged half-life offer the potential for less frequent dosing. While preclinical studies have shown encouraging results, further clinical trials are needed to fully evaluate the efficacy and safety of Reta in mammals. As a targeted approach to managing metabolic health, Reta holds promise as a future compound under investigation for study subjects with obesity and its associated comorbidities.

1. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Reta Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Reta for Obesity - A Phase 2 Trial. N Engl J Med. 2023.

2. Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Reta, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023.

3. Doggrell SA. Reta showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023.

4. Doggrell SA. Is reta (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023.

5. Harris E. Triple-Hormone Combination Reta Induces 24% Body Weight Loss. JAMA. 2023.

6. Urva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T. The novel GIP, GLP-1 and glucagon receptor agonist reta delays gastric emptying. Diabetes Obes Metab. 2023.

7. Elfeki MA, Alkhouri N. Triple-Hormone-Receptor Agonist Reta for Obesity. N Engl J Med. 2023.

8. Jastreboff AM, Kaplan LM, Hartman ML. Triple-Hormone-Receptor Agonist Reta for Obesity. Reply. N Engl J Med. 2023.

9. Ray A. Reta: a triple incretin receptor agonist for obesity management. Expert Opin Investig Drugs. 2023.

10. Bisson A, Fauchier G, Fauchier L. Triple-Hormone-Receptor Agonist Reta for Obesity. N Engl J Med. 2023.

11. Sidik S. Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective. Nature. 2023.

12. Naeem M, Imran L, Banatwala UESS. Unleashing the power of reta: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024.

13. Hong SH, Choi KM. Gut hormones and appetite regulation. Curr Opin Endocrinol Diabetes Obes. 2024.